Zobrazeno 1 - 10
of 287
pro vyhledávání: '"Kl, Hyrich"'
Autor:
Ann W. Morgan, Darren Plant, T. David, H. Firat, John D. Isaacs, Nisha Nair, A. Barton, James Oliver, Anthony G. Wilson, E. Schordan, KL Hyrich
Background:Tumour necrosis factor inhibitors (TNFi) although effective in the treatment of rheumatoid arthritis (RA), show a variable response rate. Therefore, there is a need to identify treatment response predictors to inform therapy selection in o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::276e5448ae48473ff65804557162b9f1
https://eprints.whiterose.ac.uk/185644/1/2021.08.25.21262612v1.full.pdf
https://eprints.whiterose.ac.uk/185644/1/2021.08.25.21262612v1.full.pdf
Autor:
M.M. Cunha, Ana M. Rodrigues, G.-R. Burmester, Richard Conway, Y.G. Kübra, E. Hachulla, Martin Soubrier, Olivier Brocq, Iain B. McInnes, E. Strakova, P.J.A. Gomez, Patrick Durez, Elsa F Mateus, Pedro Machado, Ludovic Trefond, E. Veillard, Loreto Carmona, M. Mosca, Xavier Mariette, N Roux, J. Zepa, T. Goulenok, Bernd Raffeiner, Saskia Lawson-Tovey, Laure Gossec, A. Strangfeld, KL Hyrich, M. Cornalba, H. Bijlsma
Publikováno v:
Revue du Rhumatisme (Ed. Francaise : 1993)
Introduction Les patients atteints de maladies musculosquelettiques inflammatoires/auto-immunes (I-RMD) n’ont pas ete inclus dans les etudes de tolerance des vaccins contre le SARS-CoV-2 et sont souvent inquiets quant a la tolerance de la vaccinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9562a6246d6157e15b76d35135e1970
http://europepmc.org/articles/PMC8626106
http://europepmc.org/articles/PMC8626106
Autor:
Catalin Codreanu, Burkhard F. Leeb, Ori Elkayam, KL Hyrich, T.K. Kvien, Anja Strangfeld, Manuel Pombo-Suarez, D. De Cock, Axel Finckh, Galina Lukina, Sytske Anne Bergstra, Karel Pavelka, Dan Nordström, Kim Lauper, Nevsun Inanc, Z. Rotar, Denis Choquette, M. J. Santos, Delphine S. Courvoisier, Denis Mongin, Florenzo Iannone, Eirik Kristianslund, Lene Dreyer
Publikováno v:
Annals of the Rheumatic Diseases. 80:256-257
Background:Industry, regulators, and the rheumatology community have recognized the need for observational studies to monitor the safety of new antirheumatic agents. Registries provide a unique opportunity to understand the safety of newer therapies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db4f92a0b6e6ab21a772181ad36861c1
https://doi.org/10.1136/annrheumdis-2021-eular.2216
https://doi.org/10.1136/annrheumdis-2021-eular.2216
Autor:
Bernd Raffeiner, Elsa F Mateus, Pedro Machado, I.B. McInnes, J. A. Gómez-Puerta, E. Hachulla, Olivier Brocq, Laure Gossec, Ludovic Trefond, Tiphaine Goulenok, H. Bijlsma, M. Cornalba, E. Veillard, L. Carmona, G.-R. Burmester, Saskia Lawson-Tovey, Patrick Durez, KL Hyrich, Marta Mosca, Julien Henry, J.-E. Gottenberg, Xavier Mariette, Anja Strangfeld
Publikováno v:
Annals of the Rheumatic Diseases. 80:199-200
Background:The consequences of the COVID-19 outbreak are unprecedented and have been felt by everyone around the world, including people with rheumatic and musculoskeletal diseases (RMDs). With the development of vaccines, the future is becoming brig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdaf47ce6204b058698abc93ed139ac2
https://doi.org/10.1136/annrheumdis-2021-eular.5097
https://doi.org/10.1136/annrheumdis-2021-eular.5097
Autor:
Pedro Machado, M. J. Santos, Anja Strangfeld, Tanja Stamm, M. de Wit, Sytske Anne Bergstra, Axel Finckh, Simon Stones, Ziga Rotar, KL Hyrich, Thomas Frisell, Delphine S. Courvoisier, Joanna Kedra, L. Midtbøll Ørnbjerg, Kim Lauper, Robert Landewé, Bruno Fautrel, Florenzo Iannone
Publikováno v:
Annals of the Rheumatic Diseases. 79:124-125
Background:Comparing drug effectiveness in observational settings is hampered by several major threats, among them confounding and attrition bias bias (patients who stop treatment no longer contribute information, which may overestimate true drug eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fcb7245b145299bb5eb8c6cfd0a93c1
https://doi.org/10.1136/annrheumdis-2020-eular.1162
https://doi.org/10.1136/annrheumdis-2020-eular.1162
Autor:
Galina Lukina, Denis Mongin, Karel Pavelka, Burkhard F. Leeb, Eirik Kristianslund, Ziga Rotar, T.K. Kvien, Manuel Pombo-Suarez, Dan Nordström, Delphine S. Courvoisier, Ori Elkayam, Lene Dreyer, KL Hyrich, M. J. Santos, Kim Lauper, Denis Choquette, Sytske Anne Bergstra, Nevsun Inanc, Anja Strangfeld, D. De Cock, Axel Finckh, Florenzo Iannone, Catalin Codreanu
Publikováno v:
Annals of the Rheumatic Diseases. 79:146-147
Background:In many countries, JAK-inhibitors (JAKi) have only recently been approved as treatment for patients with rheumatoid arthritis (RA).Objectives:To evaluate the effectiveness of JAKi compared to bDMARDs in RA patients in the real-world popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22099aefa1a725a36ae4278cd5209dc5
https://doi.org/10.1136/annrheumdis-2020-eular.346
https://doi.org/10.1136/annrheumdis-2020-eular.346
Autor:
Adeline Ruyssen-Witrand, B. Combe, Alex J. MacGregor, KL Hyrich, J. Chipping, Nathalie Rincheval, Sam Norton, Bruno Fautrel, Mark Lunt, S. M. M. Verstappen, James M. Gwinnutt
Publikováno v:
Annals of the Rheumatic Diseases. 80:110.2-111
Background:Long-term studies in rheumatoid arthritis (RA) have reported low inflammation yet high disability over time. It is important to determine which factors are driving this disparity, so appropriate interventions can be used to reduce this gap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aa9ac85da3d78815d18d1a8841eb320
https://doi.org/10.1136/annrheumdis-2021-eular.1770
https://doi.org/10.1136/annrheumdis-2021-eular.1770
Publikováno v:
Annals of the Rheumatic Diseases. 80:97.1-98
Background:In children and young people (CYP) with JIA, we have previously identified clusters with different patterns of disease impact following methotrexate (MTX) initiation. It is unclear whether clusters of treatment response following etanercep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc205d5de093295af0bd3c3b518060d6
https://doi.org/10.1136/annrheumdis-2021-eular.2505
https://doi.org/10.1136/annrheumdis-2021-eular.2505
Autor:
Jinoos Yazdany, L. Mathias, A E Clarke, Kristin M. D’Silva, Zachary S. Wallace, S. Al Emadi, Graciela S. Alarcón, Elena Nikiphorou, Emily L Gilbert, P.P. Katz, Milena A. Gianfrancesco, Andrea M Seet, C. Reategui Sokolova, Philip Robinson, Leanna Wise, Sasha Bernatsky, Ranjeny Thomas, Beth I Wallace, Naomi Serling-Boyd, Guillermo J. Pons-Estel, Manuel F. Ugarte-Gil, Vanessa L. Kronzer, Tiffany Hsu, Wendy Costello, Jonathan S. Hausmann, P. Dieudé, Rebecca Grainger, Elsa F Mateus, Pedro Machado, Suleman Bhana, Stephanie Rush, Gabriela Schmajuk, KL Hyrich, Laura Trupin, Jean W. Liew, Paul Sufka, N. Lim, Lindsay Jacobsohn, Akpabio Akanimo Akpabio, Laure Gossec, Maria José Santos, Maria O Valenzuela-Almada, Zara Izadi, Namrata Singh, L. Carmona, Saskia Lawson-Tovey, Jeffrey A. Sparks, Alí Duarte-García, Emily Sirotich, Anja Strangfeld
Publikováno v:
Annals of the Rheumatic Diseases. 80:173.2-175
Background:An increased risk of severe COVID-19 outcomes may be seen in patients with autoimmune diseases on moderate to high daily doses of glucocorticoids, as well as in those with comorbidities. However, specific information about COVID-19 outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::323e4a03e4716c69e94ca36f573f374e
https://doi.org/10.1136/annrheumdis-2021-eular.2984
https://doi.org/10.1136/annrheumdis-2021-eular.2984
Autor:
Anja Strangfeld, Jakub Zavada, M. Schaefer, C. Tellenbach, KL Hyrich, Lianne Kearsley-Fleet, M. Lagová, Jesús T. Sánchez-Costa, Carlos Sánchez-Piedra, Delphine S. Courvoisier, N. Montero, Kim Lauper, Edward Burn, D Prieto-Alhambra, D. Huschek
Publikováno v:
Annals of the Rheumatic Diseases. 80:58.2-59
Background:The Observational and Medical Outcomes Partnerships (OMOP) common data model (CDM) provides a framework for standardising health data with a view towards federated analyses, thus maximising the use and power of combining disparate datasets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d2e1d8af5b54c656075e83148009656
https://doi.org/10.1136/annrheumdis-2021-eular.888
https://doi.org/10.1136/annrheumdis-2021-eular.888